US2017136038A1PendingUtilityA1
Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue Regeneration
Est. expiryApr 6, 2031(~4.7 yrs left)· nominal 20-yr term from priority
Inventors:Shunlin Ren
A61P 3/06A61P 3/10A61P 9/00A61P 9/10A61P 29/00A61P 1/00A61P 1/16A01K 2207/25A01K 67/027A61K 48/005A01K 2267/0362C12N 9/13C12N 2799/022A61K 31/575A01K 2227/105
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S.
Claims
exact text as granted — not AI-modified1 . A method for promoting liver cell proliferation or liver tissue regeneration in a subject, comprising:
elevating a level of 25-hydroxycholesterol-3-sulfate (25HC3S) in a subject in need of at least one of liver cell proliferation and liver tissue regeneration in order to promote proliferation of liver cells or regeneration of liver tissue in said subject.
2 . The method of claim 1 wherein said elevating a level of 25HC3S is performed by administration of exogenous 25HC3S to said subject.
3 . The method of claim 2 wherein the 25HC3S is administered in an amount ranging from 0.1 mg/kg to 100 mg/kg, based on body mass of said subject.
4 . The method of claim 2 wherein the 25HC3S is administered in an amount ranging from 1 mg/kg to 10 mg/kg, based on body mass of said subject.
5 . The method of claim 2 wherein the administration comprises at least one of oral administration, enteric administration, sublingual administration, transdermal administration, intravenous administration, peritoneal administration, parenteral administration, administration by injection, subcutaneous injection, and intramuscular injection.
6 - 7 . (canceled)
8 . The method of claim 1 wherein said elevating is performed before, during or after liver surgery in said subject.
9 . The method of claim 8 wherein the liver surgery comprises liver transplant surgery.
10 . The method of claim 1 wherein said subject has at least one of cirrhosis, liver injury, and hepatitis.
11 - 16 . (canceled)
17 . A method for treating or preventing hyperlipidemia or fatty liver disease or a malady resulting from hyperlipidemia or fatty liver disease, comprising:
providing a subject with a sufficient amount of a sulfotransferase to elevate endogenous levels of 25HC3S in said subject, wherein said elevated endogenous levels of 25HC3S are sufficient to decrease lipid synthesis in said subject so as to reduce serum and hepatic lipid levels in said subject, or to reduce one or more regulators of lipid metabolism in said subject.
18 . The method of claim 17 wherein said sulfotransferase is SULT2B1b.
19 - 21 . (canceled)
22 . The method of claim 17 wherein said hyperlipidemia is selected from hypercholestolemia and hypertrigyceridemia.
23 . The method of claim 17 wherein said fatty liver disease is non-alcoholic fatty liver disease.
24 . The method of claim 17 wherein said malady comprises at least one malady selected from atherosclerosis, stroke, gall stones, diabetes, inflammatory bowel disease, and non-alcoholic steatohepatitis.
25 . (canceled)Join the waitlist — get patent alerts
Track US2017136038A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.